Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902-Comparison of administration interval in cetuximab treatment.

被引：0
|
作者：
Komatsu, Yoshito
Yuki, Satoshi
Nakatsumi, Hiroshi
Hosokawa, Ayumu
Nakamura, Michio
Muto, Osamu
Meguro, Takashi
Iwanaga, Ichiro
Hatanaka, Kazuteru
Tsuji, Yasushi
Sato, Atsushi
Eto, Kazunori
Furukawa, Kouichi
Onodera, Manabu
Tateyama, Miki
Takahashi, Yasuo
Dazai, Masayoshi
Yokoyama, Sachio
Honda, Takuya
Sakata, Yuh
机构：
[1] Hokkaido Univ Hosp, Ctr Canc, Dept Canc Chemotherapy, Sapporo, Hokkaido 060, Japan
[2] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido 060, Japan
[3] Toyama Univ, Fac Med, Dept Gastroenterol & Hematol, Toyama 930, Japan
[4] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[5] Japanese Red Cross Akita Hosp, Dept Med Oncol, Akita, Japan
[6] Hokkaido Gastroenterol Hosp, Sapporo, Hokkaido, Japan
[7] Japanese Red Cross Kitami Hosp, Dept Gastroenterol, Kitami, Hokkaido, Japan
[8] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan
[9] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[10] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan
[11] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan
[12] Niigata City Gen Hosp, Niigata, Japan
[13] Abashiri Kosei Gen Hosp, Dept Gastroenterol, Abashiri, Japan
[14] Tomakomai Nisshou Hosp, Dept Internal Med, Tomakomai, Japan
[15] Hokkaido Canc Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[16] Kushiro Rosai Hosp, Dept Internal Med, Kushiro, Hokkaido, Japan
[17] Kumamoto City Hosp, Dept Surg, Kumamoto, Japan
[18] Nagasaki Univ, Dept Gastroenterol & Hepatol, Grad Sch Biomed Sci, Nagasaki 852, Japan
[19] Misawa City Hosp, Misawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
746
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
    Toshi Takaoka
    Tetsuo Kimura
    Rai Shimoyama
    Shunji Kawamoto
    Kazuki Sakamoto
    Fuminori Goda
    Hiroshi Miyamoto
    Yuji Negoro
    Akihito Tsuji
    Koji Yoshizaki
    Takahiro Goji
    Shinji Kitamura
    Hiromi Yano
    Koichi Okamoto
    Masako Kimura
    Toshiya Okahisa
    Naoki Muguruma
    Yoshiro Niitsu
    Tetsuji Takayama
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 397 - 403
  • [22] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
    Takaoka, Toshi
    Kimura, Tetsuo
    Shimoyama, Rai
    Kawamoto, Shunji
    Sakamoto, Kazuki
    Goda, Fuminori
    Miyamoto, Hiroshi
    Negoro, Yuji
    Tsuji, Akihito
    Yoshizaki, Koji
    Goji, Takahiro
    Kitamura, Shinji
    Yano, Hiromi
    Okamoto, Koichi
    Kimura, Masako
    Okahisa, Toshiya
    Muguruma, Naoki
    Niitsu, Yoshiro
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 397 - 403
  • [23] Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer
    Hoyle, Martin
    Peters, Jaime
    Crathorne, Louise
    Jones-Hughes, Tracey
    Cooper, Chris
    Napier, Mark
    Hyde, Chris
    VALUE IN HEALTH, 2013, 16 (02) : 288 - 296
  • [24] Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
    Loupakis, F.
    Cremolini, C.
    Perrone, G.
    Stasi, I.
    Salvatore, L.
    Vincenzi, B.
    Ruzzo, A.
    Ronzoni, M.
    Bencardino, K.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan plus Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
    Sobrero, Alberto
    Lenz, Heinz-Josef
    Eng, Cathy
    Scheithauer, Werner
    Middleton, Gary
    Chen, Wenfeng
    Esser, Regina
    Nippgen, Johannes
    Burris, Howard
    ONCOLOGIST, 2021, 26 (02): : E261 - E269
  • [26] Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)
    Sobrero, A.
    Lenz, H-J.
    Eng, C.
    Scheithauer, W.
    Middleton, G.
    Chen, W.
    Esser, R.
    Nippgen, J.
    Burris, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 163 - 163
  • [27] Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study
    Iwamoto, Shigeyoshi
    Hazama, Shoichi
    Kato, Takeshi
    Miyake, Yasuhiro
    Fukunaga, Mutsumi
    Matsuda, Chu
    Bando, Hiroyuki
    Sakamoto, Junichi
    Oba, Koh
    Mishima, Hideyuki
    ANTICANCER RESEARCH, 2014, 34 (04) : 1967 - 1973
  • [28] Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial-Comparison of the efficacy of KRAS status
    Nakamura, Michio
    Yuki, Satoshi
    Dazai, Masayoshi
    Kobayashi, Yoshimitsu
    Kato, Takashi
    Naruse, Hirohito
    Kudo, Mineo
    Akakura, Nobuaki
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [29] Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
    Ye Chen
    Dan Cao
    Feng Bi
    Qiu Li
    Meng Qiu
    Medical Oncology, 2014, 31
  • [30] Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
    Chen, Ye
    Cao, Dan
    Bi, Feng
    Li, Qiu
    Qiu, Meng
    MEDICAL ONCOLOGY, 2014, 31 (05)
12345